2024.07.02 (화)

  • 흐림동두천 22.7℃
  • 흐림강릉 22.8℃
  • 서울 24.4℃
  • 대전 21.1℃
  • 대구 21.9℃
  • 울산 21.6℃
  • 흐림광주 25.0℃
  • 부산 23.1℃
  • 흐림고창 24.4℃
  • 구름조금제주 28.8℃
  • 흐림강화 23.2℃
  • 흐림보은 21.8℃
  • 흐림금산 20.9℃
  • 흐림강진군 24.6℃
  • 흐림경주시 22.2℃
  • 흐림거제 24.0℃
기상청 제공

경제

Competitive Technologies' Management Team Emphasized Continued Profitable Growth Plans At Annual Shareholder Meeting

NBC-1TV World News

[By NBC-1TV H. J Yook]Competitive Technologies Inc. (OTCQX:CTTC) held its annual meeting of shareholders earlier today at the Norwalk Inn and Conference Center in Norwalk, Conn. CTTC‘s Chairman, William Reali reviewed the company’s performance and the management team of Mr. Reali, CEO Johnnie D. Johnson and EVP Aris Despo provided highlights of the company‘s sales plan for its Calmare® pain therapy medical device. Emphasizing the company’s team approach, Mr. Johnson read supportive remarks provided by Professor Giuseppe Marineo, inventor of the “Scrambler Therapy” technology underlying the Calmare® device. S.B. Oh, EVP of GEOMC Co., Ltd. of Korea, which manufactures the Calmare® device for CTTC attended the meeting, also showing support of CTTC's plans.

At the meeting, CTTC shareholders re-elected the company‘s four sitting directors, including Mr. Reali, Joel M. Evans, MD, Richard D. Hornidge, and Rustin Howard. In addition, shareholders ratified the appointment of Mayer Hoffman McCann CPAs as CTTC’s independent public accounting firm.

Anticipated revenues for the first quarter of 2011 will primarily be from the sale of 72 Calmare® devices with a gross value of $1.9 million, of which CTTC‘s share is approximately one half. Anticipated benefits from the company’s other technologies, including bone cement, homocysteine assays, sexual dysfunction, RFID, and specimen cups, were also discussed. A copy of the presentation can be found under the “Investors” tab at the CTTC website: www.competitivetech.net.

“Competitive Technologies remains confident that it will be profitable throughout the fiscal year ending December 31, 2011,” said Mr. Johnson. “The management team is committed to moving this company forward and focusing on building revenues. At the forefront of our activities this year is enabling Prof. Marineo‘s ’Scrambler Therapy‘ to help more physicians relieve their patients’ neuropathic pain. As sales of the Calmare® device expand, we expect revenue and net profit to grow.”



배너

배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너